Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism
Open Access
- 27 April 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (12) , 2950-2961
Abstract
The current paradigm stipulates that inhibition of histone deacetylase (HDAC) 6 is essential for the combinatorial effect of proteasome and HDAC inhibitors for the treatment of cancers. Our study aims to investigate the effect of combining different class I HDAC inhibitors (without HDAC6 action) with a proteasome inhibitor on apoptosis of nasopharyngeal carcinoma (NPC). We found that combination of a proteasome inhibitor, bortezomib, and several class I HDAC inhibitors, including MS-275, apicidin and romidepsin, potently induced killing of NPC cells both in vitro and in vivo. Among the drug pairs, combination of bortezomib and romidepsin (bort/romidepsin) was the most potent and could induce apoptosis at low nanomolar concentrations. The apoptosis of NPC cells was reactive oxygen species (ROS)- and caspase-dependent but was independent of HDAC6 inhibition. Of note, bort/romidepsin might directly suppress the formation of aggresome through the downregulation of c-myc. In addition, two markers of endoplasmic reticulum (ER) stress-induced apoptosis, ATF-4 and CHOP/GADD153, were upregulated, whereas a specific inhibitor of caspase-4 (an initiator of ER stress-induced apoptosis) could suppress the apoptosis. When ROS level in the NPC cells was reduced to the untreated level, ER stress-induced caspase activation was abrogated. Collectively, our data demonstrate a model of synergism between proteasome and class I HDAC inhibitors in the induction of ROS-dependent ER stress-induced apoptosis of NPC cells, independent of HDAC6 inhibition, and provide the rationale to combine the more specific and potent class I HDAC inhibitors with proteasome inhibitors for the treatment of cancers.Keywords
This publication has 47 references indexed in Scilit:
- Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C TerminiJournal of Biological Chemistry, 2012
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011
- Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesInvestigational New Drugs, 2010
- The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanismBritish Journal of Haematology, 2010
- Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repairProceedings of the National Academy of Sciences, 2010
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapyProceedings of the National Academy of Sciences, 2010
- Dual Involvement of Caspase-4 in Inflammatory and ER Stress-Induced Apoptotic Responses in Human Retinal Pigment Epithelial CellsInvestigative Ophthalmology & Visual Science, 2009
- Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHABlood, 2008
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsBlood, 2006